Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 50.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,305 shares of the biopharmaceutical company’s stock after selling 25,495 shares during the period. Headlands Technologies LLC’s holdings in Ultragenyx Pharmaceutical were worth $845,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RARE. BlackRock Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $355,746,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $6,397,000. Deutsche Bank AG purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth $5,503,000. Blue Owl Capital Holdings LP purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $6,098,000. Finally, Ieq Capital LLC acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $3,540,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Up 2.4%

Shares of RARE opened at $25.81 on Wednesday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $39.89. The stock’s 50 day moving average is $28.41 and its two-hundred day moving average is $25.06. The firm has a market capitalization of $2.54 billion, a PE ratio of -4.42 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company’s revenue for the quarter was up 28.5% on a year-over-year basis. During the same period in the prior year, the business posted ($1.17) EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.97 EPS for the current year.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of recent research reports. Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. upped their price target on Ultragenyx Pharmaceutical from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 25th. Citigroup increased their price target on Ultragenyx Pharmaceutical from $45.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Royal Bank Of Canada lifted their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.44.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director directly owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.20% of the stock is owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.